LIST OF FIGURES

Figure 1  Electrophoretic pattern of total human heart extract (THHE) in 5-20% gradient SDS-PAGE 76
Figure 2  Elution profile of purification of electroeluted 150 kD human cardiac C-protein by HPLC 77
Figure 3  Agarose gel electrophoresis to show the absence of any trace of DNA in THHE 78
Figure 4  Circular dichroic spectra of 150 kD human cardiac C-protein 80
Figure 5  Thermal denaturation profile of HPLC purified 150 kD human cardiac C-protein 81
Figure 6  Electrophoretic pattern of C-protein and IgG on urea SDS-PAGE 87
Figure 7  Binding of anti C-protein antibody in rabbit with C-protein 89
Figure 8  Binding of anti C-protein antibody in rat with C-protein 89
Figure 9  Inhibition of anti C-protein antibody in rabbit with C-protein 90
Figure 10 Inhibition of anti C-protein antibody in rat with C-protein 90
Figure 11 Elution profile of IgG on protein-A-sepharose CL - 4B column 92
Figure 12 Binding of DCM and immune IgG with C-protein 93
Figure 13 Inhibition of immune IgG activity by native and ROS C-protein 95
Figure 14: Inhibition of immune IgG activity by nDNA C-protein adducts/photoadducts.

Figure 15: Inhibition of immune IgG activity by native and ROS histone.

Figure 16: Inhibition of immune IgG activity by Poly-L-lysine, Poly-L-glutamate and Poly (L+G) complex.

Figure 17: Inhibition of immune IgG activity by ROS DNA and RNA.

Figure 18: Direct Binding ELISA of THHE with DCM autoantibodies.

Figure 19: Inhibition ELISA of DCM autoantibodies with C-protein as inhibitor.

Figure 20: Direct binding ELISA of DCM autoantibodies with 150 kD C-protein.

Figure 21: Direct binding ELISA of DCM autoantibodies with native DNA.

Figure 22: Inhibition of DCM IgG activity by native and ROS C-protein.

Figure 23: Inhibition of DCM IgG activity by nDNA C-protein adducts/photoadducts.

Figure 24: Inhibition of DCM IgG activity by native and ROS modified histone.

Figure 25: Inhibition of DCM IgG activity by Poly-D-lysine, Poly-L-Glutamate and Poly (L+G) complex.

Figure 26: Inhibition of DCM IgG activity by ROS DNA and RNA.

Figure 27: Time course pattern of nDNA-C-protein photoadducts formed by UV-B irradiation.
Figure 28  UV absorption characteristics of irradiated nDNA-C-protein  116
Figure 29  UV absorption characteristics of nDNA-C-protein and their adducts after ROS modification  119
Figure 30  Electrophoretic mobility of nDNA-C-protein and their adducts after ROS modification  121
Figure 31  Nuclease S1 sensitivity assay of nDNA-C-protein adducts/photoadducts  122
Figure 32  Time course kinetic profile of photoaddition of C-protein to native DNA  124
Figure 33  Standard plot for estimation of lysine by TBS method  125
Figure 34  Kinetic profile of photobound lysine residues (present in C-protein) to nDNA  126
Figure 35  Apparent first order kinetic profile of nDNA-C-protein photoadducts formation at various irradiation times  127
Figure 36  Immunoaffinity purification of SLE IgG on nDNA polylysyl sepharose 4B column  129
Figure 37  Binding of nDNA C-protein photoadduct with DCM, SLE and immune IgG  131
Figure 38  Binding of ROS DNA C-protein adduct with DCM, SLE and immune IgG  132
Figure 39  Binding of ROS DNA C-protein photoadduct with DCM, SLE and immune IgG  133
Figure 40  Binding of SLE autoantibodies with dsDNA, ssDNA, RNA and THHE  134
Figure 41: Inhibition ELISA of SLE autoantibodies with DNA, ssDNA and RNA as inhibitors on plates coated with ds DNA.

Figure 42: Inhibition ELISA of SLE autoantibodies with THHE as inhibitor on plates coated with ds DNA.

Figure 43: Inhibition ELISA of protein-A-sepharose isolated SLE IgG with 150 kD C-protein on plates coated with ds DNA.

Figure 44: Inhibition ELISA of immunoaffinity purified SLE IgG with 150 kD C-protein on plates coated with ds DNA.

Figure 45: Direct binding ELISA of DCM autoantibodies with native and ROS mt DNA.

Figure 46: Inhibition ELISA of DCM autoantibodies with native mt DNA as competitor.

Figure 47: Inhibition ELISA of DCM autoantibodies with ROS mt DNA as competitor.

Figure 48: Glucose levels in sera of patients with DCM.

Figure 49: Total serum cholesterol levels in patients with DCM.

Figure 50: Levels of uric acid in sera of patients with DCM.

Figure 51: C-reactive protein (CRP) level in sera of patients with DCM.